A Phase 2 interventional study of ONO-1110 and Placebo in Postherpetic Neuralgia, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 31 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Neuralgia, Postherpetic with a site in Japan — none open to participants now, none under way, none of them phase 3. Neuralgia, Postherpetic · Japan.
Among the 11 studies in Neuralgia, Postherpetic with a site in Japan, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, and was the 11th registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →None of the 11 studies in Neuralgia, Postherpetic with a site in Japan is open now. The open studies under Neuralgia, Postherpetic, anywhere →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 136 across the 10 interventional studies, 448 across the 1 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 1 study filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Neuralgia, Postherpetic with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of ONO-1110 in Japanese patients with postherpetic neuralgia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ONO-1110 tablets once a day
Drug: ONO-1110
Placebo tablets once daily
Drug: Placebo
ONO-1110 tablets once a day
Placebo tablets once daily
Change in weekly mean of average pain score (last 7-day mean of past 24-hour average pain scores [NRS] in the pain diary) from baseline to Week 8 of the treatment period
Time frame: Up to 15 weeks
Adverse Events
Time frame: Up to 15 weeks
Change in weekly mean of average pain score from baseline to each week
Time frame: Up to 15 weeks
30%- and 50%-responder rates based on the weekly mean of average pain score (proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively)
Time frame: Up to 15 weeks
Change in weekly mean of worst pain score (last 7-day mean of past 24-hour worst pain scores [NRS] in the pain diary) from baseline to each week
Time frame: Up to 15 weeks
30%- and 50%-responder rates based on the weekly mean of worst pain score (proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively)
Time frame: Up to 15 weeks
Change in Brief pain inventory-short form (BPI-SF) score from baseline
Time frame: Up to 15 weeks
Change in Short Form McGill Pain Questionnaire-2 (SF-MPQ-2) score from baseline
Time frame: Up to 15 weeks
Patient Global Impression of Change (PGIC) score
Time frame: Up to 15 weeks
Change in Hospital Anxiety and Depression Scale (HADS) score from baseline
Time frame: Up to 15 weeks
Plasma ONO-1110 concentrations
Time frame: Up to 15 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in May 2026, 14 months.
Of 12 phase 2 interventional studies under Neuralgia, Postherpetic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 14 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ONO-1110
Ono Pharmaceutical Co., Ltd. →